Phase 2 N=10 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Ewing's Sarcoma Family of Tumors
Primary: Objective Response Rate (ORR) — 14.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Phase 2 N=10 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Sarcoma
Primary: Response — 10; 0 participants
Phase 2 N=38 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Phase 3 N=642 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
N/A N=35 Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Ewing Sarcoma of Bone · Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Primary: Incidence of Death — 0 participants
Phase 1 N=65 Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Phase 2 N=10 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Phase 2 N=7 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Phase 2 N=17 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 2 N=22 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Ewing's Sarcoma
Primary: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations — 5; 6; 9 Participants
Phase 2 N=9 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
Phase 2 N=16 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
Phase 2 N=21 Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Relapsed/Refractory Rhabdomyosarcoma · Non-rhabdomyosarcoma Soft Tissue Sarcoma · Ewing Sarcoma
Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants
Phase 1 N=50 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants
Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 2 N=54 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Phase 2 N=113 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) · Rhabdomyosarcoma · Leiomyosarcoma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants
Phase 3 N=109 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Phase 2 N=128 E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Progression Free Survival (PFS) at 12 Weeks — 46.9; 31.6; 21.1; 19.2 Percentage of participants
Phase 1 N=2 NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
Sarcoma
Primary: Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03 — 1; 1; 1; 1 participants
Phase 2 N=11 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Sarcoma
Primary: Tumor Response — 10 participants
Phase 2 N=98 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
Lymphedema · Musculoskeletal Complications · Radiation Fibrosis
Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…
Phase 2 N=19 Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 0 participants